Graig Suvannavejh
Stock Analyst at Mizuho
(2.24)
# 2,655
Out of 4,876 analysts
151
Total ratings
42.98%
Success rate
-4.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Maintains: Outperform | $16 → $12 | $2.44 | +391.80% | 5 | Jun 26, 2025 | |
| ADAP Adaptimmune Therapeutics | Downgrades: Neutral | $1.5 → $0.5 | $0.24 | +112.77% | 3 | Jun 26, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $8 → $10 | $3.60 | +178.16% | 2 | Jun 18, 2025 | |
| INSM Insmed | Maintains: Outperform | $96 → $110 | $101.55 | +8.32% | 7 | Jun 11, 2025 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $12 → $11 | $4.00 | +175.00% | 2 | May 20, 2025 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Outperform | $30 → $26 | $10.01 | +159.74% | 5 | May 16, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $44 → $48 | $31.90 | +50.47% | 18 | May 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $30 → $20 | $17.96 | +11.36% | 7 | May 14, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Outperform | $7 → $8 | $6.30 | +26.98% | 7 | May 14, 2025 | |
| IMCR Immunocore Holdings | Maintains: Neutral | $38 → $33 | $31.93 | +3.35% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $212 → $216 | $106.09 | +103.60% | 21 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $2.29 | +231.88% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $7.82 | +846.29% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $0.5 | $0.31 | +60.56% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $49 | $52.86 | -7.30% | 6 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $21.92 | +128.10% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $0.80 | +2,391.28% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $5.55 | +188.29% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $3.83 | +161.44% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $1.47 | +512.24% | 4 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $64 | $1.92 | +3,233.33% | 8 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $3.21 | -68.85% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $7.95 | +88.80% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $62.26 | -43.78% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $3.73 | +114.48% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $33.55 | +69.90% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $37.70 | -86.74% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $5.65 | +501.63% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $3.69 | +658.81% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $13.28 | +133.43% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $1.05 | +1,709.52% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.87 | +154.01% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $13.68 | +163.16% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $28.05 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $0.83 | +4,357.83% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $108.87 | +17.58% | 1 | Sep 14, 2020 |
Adverum Biotechnologies
Jun 26, 2025
Maintains: Outperform
Price Target: $16 → $12
Current: $2.44
Upside: +391.80%
Adaptimmune Therapeutics
Jun 26, 2025
Downgrades: Neutral
Price Target: $1.5 → $0.5
Current: $0.24
Upside: +112.77%
Immuneering
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $3.60
Upside: +178.16%
Insmed
Jun 11, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $101.55
Upside: +8.32%
Corvus Pharmaceuticals
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $4.00
Upside: +175.00%
EyePoint Pharmaceuticals
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $10.01
Upside: +159.74%
Harmony Biosciences Holdings
May 15, 2025
Maintains: Outperform
Price Target: $44 → $48
Current: $31.90
Upside: +50.47%
Apellis Pharmaceuticals
May 14, 2025
Maintains: Neutral
Price Target: $30 → $20
Current: $17.96
Upside: +11.36%
Amylyx Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $6.30
Upside: +26.98%
Immunocore Holdings
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $31.93
Upside: +3.35%
Mar 27, 2025
Maintains: Outperform
Price Target: $212 → $216
Current: $106.09
Upside: +103.60%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $2.29
Upside: +231.88%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $7.82
Upside: +846.29%
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.31
Upside: +60.56%
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $52.86
Upside: -7.30%
Jul 8, 2024
Initiates: Outperform
Price Target: $50
Current: $21.92
Upside: +128.10%
Jul 8, 2024
Initiates: Outperform
Price Target: $20
Current: $0.80
Upside: +2,391.28%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $5.55
Upside: +188.29%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $3.83
Upside: +161.44%
Nov 17, 2023
Maintains: Buy
Price Target: $10 → $9
Current: $1.47
Upside: +512.24%
Aug 23, 2023
Reiterates: Neutral
Price Target: $64
Current: $1.92
Upside: +3,233.33%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $3.21
Upside: -68.85%
Mar 31, 2023
Initiates: Buy
Price Target: $15
Current: $7.95
Upside: +88.80%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $62.26
Upside: -43.78%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $3.73
Upside: +114.48%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $33.55
Upside: +69.90%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $37.70
Upside: -86.74%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $5.65
Upside: +501.63%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $3.69
Upside: +658.81%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $13.28
Upside: +133.43%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $1.05
Upside: +1,709.52%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.87
Upside: +154.01%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $13.68
Upside: +163.16%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $28.05
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $0.83
Upside: +4,357.83%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $108.87
Upside: +17.58%